2024-03-28T19:15:07Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00028457
2023-11-16T02:58:17Z
499:508:509:2431
Tegafur and 5-fluorouracil levels in tears and changes in tear volume in long-term users of the oral anticancer drug S-1
Kuriki, Reiko
Hata, Tsuyoshi
Nakayama, Kinuyo
Ito, Yuichi
Misawa, Kazunari
Ito, Seiji
Tatematsu, Michiko
Kaneda, Norio
open access
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
S-1
tegafur
5-fluorouracil
watering eyes
LC-MS/MS
Eye problems are an adverse reaction sometimes found in chemotherapy. Although not life-threatening, they can reduce patients’ quality of life. The highest incidence of eye problems is reported for the combination anticancer drug S-1 (tegafur–gimeracil–oteracil), and methods to prevent or treat the eye problems caused by this drug are presently lacking. To determine early detection methods and treatment for adverse ocular reactions, we measured changes in tear volume and levels of tegafur (FT) and 5-fluorouracil (5-FU), an active metabolite of FT, in the tears of patients with long-term use of S-1. A total of 11 patients receiving S-1 monotherapy as adjuvant chemotherapy after gastric cancer surgery were included. Tear volume and FT and 5-FU levels in tears were measured by liquid chromatography with tandem mass spectrometry during a maximum of 8 treatment cycles (48 weeks). For analysis, patients were divided into two groups: “watering eyes” (n=6, complaints of watering eyes at least once during the treatment period) and “no watering eyes” (n=5, no complaints of watering eyes). Both groups exhibited increased FT and 5-FU levels in tears upon initiation of S-1 treatment, and levels rapidly decreased upon discontinuation. Our findings suggest a relationship between FT level in tears and tear volume in patients with long-term S-1 use. The symptom of watering eyes may thus be linked to FT level in tears.
Nagoya University Graduate School of Medicine, School of Medicine
2019-08
eng
departmental bulletin paper
VoR
https://doi.org/10.18999/nagjms.81.3.415
http://hdl.handle.net/2237/00030648
https://nagoya.repo.nii.ac.jp/records/28457
10.18999/nagjms.81.3.415
http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/813.html
2186-3326
0027-7622
Nagoya Journal of Medical Science
81
3
415
425
https://nagoya.repo.nii.ac.jp/record/28457/files/07_Kuriki.pdf
application/pdf
2.0 MB
2019-09-04